Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt
· Delayed Price · Currency is EGP 4.550
-0.060 (-1.30%)
At close: Apr 28, 2026
EGX:RMDA Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 4,096 | 2,769 | 1,922 | 1,484 | 1,246 | Upgrade
|
| Revenue Growth (YoY) | 47.94% | 44.03% | 29.54% | 19.06% | 29.81% | Upgrade
|
| Cost of Revenue | 2,114 | 1,485 | 1,018 | 765.28 | 669.61 | Upgrade
|
| Gross Profit | 1,982 | 1,284 | 904.06 | 718.67 | 576.82 | Upgrade
|
| Selling, General & Admin | 907.93 | 558.11 | 444.06 | 360.96 | 303.18 | Upgrade
|
| Other Operating Expenses | -8.98 | -27.3 | -7.34 | -6.04 | -0.76 | Upgrade
|
| Operating Expenses | 1,020 | 558.54 | 458.3 | 376.41 | 302.53 | Upgrade
|
| Operating Income | 962.45 | 725.44 | 445.76 | 342.26 | 274.29 | Upgrade
|
| Interest Expense | -531.27 | -307.21 | -191.2 | -89.07 | -91.03 | Upgrade
|
| Interest & Investment Income | 18.81 | 65.85 | 62.9 | 56.73 | 59.97 | Upgrade
|
| Currency Exchange Gain (Loss) | -6.14 | 56.24 | 18.68 | 25.65 | -0.6 | Upgrade
|
| Other Non Operating Income (Expenses) | -17.34 | -11.7 | -8.84 | -6.99 | -8.31 | Upgrade
|
| EBT Excluding Unusual Items | 426.51 | 528.62 | 327.31 | 328.58 | 234.33 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.15 | 0.01 | 0.14 | -0.13 | -0.72 | Upgrade
|
| Asset Writedown | -2.56 | -2.51 | - | - | - | Upgrade
|
| Pretax Income | 424.1 | 526.12 | 327.45 | 328.45 | 233.61 | Upgrade
|
| Income Tax Expense | 110.89 | 124.31 | 74.24 | 75.57 | 53.52 | Upgrade
|
| Earnings From Continuing Operations | 313.21 | 401.81 | 253.21 | 252.89 | 180.09 | Upgrade
|
| Minority Interest in Earnings | -14.75 | -14.44 | -8.35 | -7.21 | 1 | Upgrade
|
| Net Income | 298.46 | 387.37 | 244.86 | 245.68 | 181.09 | Upgrade
|
| Preferred Dividends & Other Adjustments | 29.85 | 23.53 | 21.36 | 16.76 | 14.7 | Upgrade
|
| Net Income to Common | 268.61 | 363.84 | 223.5 | 228.91 | 166.39 | Upgrade
|
| Net Income Growth | -22.95% | 58.20% | -0.33% | 35.67% | 61.43% | Upgrade
|
| Shares Outstanding (Basic) | 2,000 | 2,002 | 1,973 | 1,952 | 2,015 | Upgrade
|
| Shares Outstanding (Diluted) | 2,010 | 2,009 | 1,987 | 1,962 | 2,015 | Upgrade
|
| Shares Change (YoY) | 0.02% | 1.11% | 1.27% | -2.62% | - | Upgrade
|
| EPS (Basic) | 0.13 | 0.18 | 0.11 | 0.12 | 0.08 | Upgrade
|
| EPS (Diluted) | 0.13 | 0.18 | 0.11 | 0.12 | 0.08 | Upgrade
|
| EPS Growth | -26.23% | 60.98% | -3.52% | 41.22% | 70.69% | Upgrade
|
| Free Cash Flow | -199.57 | -371.85 | -135.54 | -5.03 | 188.68 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | -0.18 | -0.07 | -0.00 | 0.09 | Upgrade
|
| Dividend Per Share | - | 0.040 | 0.051 | - | - | Upgrade
|
| Dividend Growth | - | -20.71% | - | - | - | Upgrade
|
| Gross Margin | 48.39% | 46.38% | 47.03% | 48.43% | 46.28% | Upgrade
|
| Operating Margin | 23.50% | 26.20% | 23.19% | 23.06% | 22.01% | Upgrade
|
| Profit Margin | 6.56% | 13.14% | 11.63% | 15.43% | 13.35% | Upgrade
|
| Free Cash Flow Margin | -4.87% | -13.43% | -7.05% | -0.34% | 15.14% | Upgrade
|
| EBITDA | 1,046 | 804.84 | 514.61 | 403.67 | 316.61 | Upgrade
|
| EBITDA Margin | 25.53% | 29.07% | 26.77% | 27.20% | 25.40% | Upgrade
|
| D&A For EBITDA | 83.39 | 79.4 | 68.85 | 61.41 | 42.31 | Upgrade
|
| EBIT | 962.45 | 725.44 | 445.76 | 342.26 | 274.29 | Upgrade
|
| EBIT Margin | 23.50% | 26.20% | 23.19% | 23.06% | 22.01% | Upgrade
|
| Effective Tax Rate | 26.15% | 23.63% | 22.67% | 23.01% | 22.91% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.